Director/PDMR Shareholding

Regulatory News Service

26 September 2017 12:00 BST


TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announces that, on 25 September 2017, an award of the Company’s American Depositary Shares (ADSs) made under the AstraZeneca Restricted Share Plan (AZRSP) vested to Sean Bohen, a person discharging managerial responsibilities (PDMR) of the Company. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.

The AZRSP award was granted on 25 September 2015 and vested in two tranches on the first and second anniversaries of grant. Following the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Bohen became beneficially entitled to and received 12,385 ADSs.

For tax purposes, the fair market value of an ADS at vest was $33.95, being the closing price on the last trading day preceding the vesting day.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.


CONTACTS

Media Enquiries

 

 

 

 

Esra Erkal-Paler

UK/Global

+44 203 749 5638

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Enquiries

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology

+1 240 477 3771

Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

Nick Stone

Respiratory

+44 203 749 5716

US Toll-Free

 

+1 866 381 7277

 

Adrian Kemp

Company Secretary, AstraZeneca PLC

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Sean Bohen

2

 

Reason for the notification

 

a)

 

Position/status

 

Person discharging managerial responsibilities

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

AstraZeneca PLC American Depositary Shares

 

  

CUSIP: 046353108

b)

 

Nature of the transaction

 

 

Acquisition of ADSs pursuant to vesting under the AstraZeneca Restricted Share Plan, for nil consideration.

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

0

12,385

 

d)

 

Aggregated information

 

- Aggregated volume

- Price

 

Not applicable – single transaction

e)

 

Date of the transaction

 

25 September 2017

f)

 

Place of the transaction

 

Outside a trading venue

tags

  • Regulatory